The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 14 results:
[ Author(Desc)] Title Type Year
Filters: Author is Karagiannis, Thomas  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
K
Karagiannis, T., Paschos P., Paletas K., Matthews D. R., & Tsapas A. (2012).  Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.. BMJ. 344, e1369.
Karagiannis, T., Avgerinos I., Liakos A., Del Prato S., Matthews D. R., Tsapas A., et al. (2022).  Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.. Diabetologia. 65(8), 1251-1261.
Karagiannis, T., Bekiari E., & Tsapas A. (2017).  Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. Core Evidence. Volume 12, 1 - 10.
Karagiannis, T., Tsapas A., Bekiari E., Toulis K. A., & Nauck M. A. (2024).  A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes.. Diabetes Care. 47(2), 184-192.
Karagiannis, T., Bekiari E., & Tsapas A. (2017).  Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy.. Core Evid. 12, 1-10.
Karagiannis, T., Liakos A., Branda M. E., Athanasiadou E., Mainou M., Boura P., et al. (2016).  Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial. BMJ Open. 6(11), e012185.
Karagiannis, T., Bekiari E., & Tsapas A. (2023).  Socioeconomic aspects of incretin-based therapy.. Diabetologia. 66(10), 1859-1868.
Karagiannis, T., Liakos A., Branda M. E., Athanasiadou E., Mainou M., Boura P., et al. (2016).  Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial.. BMJ Open. 6(11), e012185.
Karagiannis, T., Bekiari E., Boura P., & Tsapas A. (2016).  Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications. Therapeutic Advances in Drug Safety. 7(2), 36 - 38.
Karagiannis, T., Tsapas A., & Bekiari E. (2021).  KDIGO made 12 recommendations for managing diabetes with CKD.. Ann Intern Med. 174(3), JC26.
Karagiannis, T., & Bekiari E. (2016).  Most add-on therapies to metformin have similar effects on HbA1c.. Evid Based Med. 21(6), 223.
Karagiannis, T., Boura P., & Tsapas A. (2014).  Safety of dipeptidyl peptidase 4 inhibitors: a perspective review.. Ther Adv Drug Saf. 5(3), 138-46.
Karagiannis, T., Tsapas A., Athanasiadou E., Avgerinos I., Liakos A., Matthews D. R., et al. (2021).  GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis.. Diabetes Res Clin Pract. 174, 108737.
Karagiannis, T., Bekiari E., Boura P., & Tsapas A. (2016).  Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications.. Ther Adv Drug Saf. 7(2), 36-8.

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.